过表达 microRNA-126 的间充质干细胞来源的外泌体通过靶向 PIK3R2 介导的 PI3K/Akt 信号通路促进血管生成。
Exosomes from microRNA-126 overexpressing mesenchymal stem cells promote angiogenesis by targeting the PIK3R2-mediated PI3K/Akt signalling pathway.
机构信息
Department of Orthopaedic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Department of Orthopaedic Surgery, Xi'an Children's Hospital, Xi'an, Shaanxi Province, China.
出版信息
J Cell Mol Med. 2021 Feb;25(4):2148-2162. doi: 10.1111/jcmm.16192. Epub 2020 Dec 21.
microRNA-126 (miR-126), an endothelial-specific miRNA, is associated with vascular homeostasis and angiogenesis. However, the efficiency of miR-126-based treatment is partially compromised due to the low efficiency of miRNA delivery in vivo. Lately, exosomes have emerged as a natural tool for therapeutic molecule delivery. Herein, we investigated whether exosomes derived from bone marrow mesenchymal stem cells (BMMSCs) can be utilized to deliver miR-126 to promote angiogenesis. Exosomes were isolated from BMMSCs overexpressed with miR-126 (Exo-miR-126) by ultracentrifugation. In vitro study, Exo-miR-126 treatment promoted the proliferation, migration and angiogenesis of human umbilical vein endothelial cells (HUVECs). Furthermore, the gene/protein expression of angiogenesis-related vascular endothelial growth factor (VEGF) and angiotensin-1 (Ang-1) were up-regulated after incubation with Exo-miR-126. Additionally, the expression level of phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2) showed an inverse correlation with miR-126 in HUVECs. Particularly, the Exo-miR-126 treatment contributed to enhanced angiogenesis of HUVECs by targeting PIK3R2 to activate the PI3K/Akt signalling pathway. Similarly, Exo-miR-126 administration profoundly increased the number of newly formed capillaries in wound sites and accelerated the wound healing in vivo. The results demonstrate that exosomes derived from BMMSCs combined with miR-126 may be a promising strategy to promote angiogenesis.
微小 RNA-126(miR-126)是一种内皮细胞特异性 miRNA,与血管稳态和血管生成有关。然而,由于 miRNA 在体内的递送效率低,基于 miR-126 的治疗效率部分受到限制。最近,外泌体已成为治疗分子递送的天然工具。本文研究了骨髓间充质干细胞(BMMSCs)来源的外泌体是否可用于递送 miR-126 以促进血管生成。通过超速离心从过表达 miR-126 的 BMMSCs 中分离出外泌体(Exo-miR-126)。在体外研究中,Exo-miR-126 处理可促进人脐静脉内皮细胞(HUVECs)的增殖、迁移和血管生成。此外,孵育 Exo-miR-126 后,血管生成相关血管内皮生长因子(VEGF)和血管紧张素-1(Ang-1)的基因/蛋白表达上调。此外,HUVECs 中 PIK3R2 的表达水平与 miR-126 呈负相关。特别是,通过靶向 PIK3R2 激活 PI3K/Akt 信号通路,Exo-miR-126 处理有助于增强 HUVECs 的血管生成。同样,Exo-miR-126 给药可显著增加伤口部位新形成的毛细血管数量并加速体内伤口愈合。结果表明,源自 BMMSCs 的外泌体与 miR-126 联合使用可能是促进血管生成的一种有前途的策略。
相似文献
引用本文的文献
Int J Nanomedicine. 2025-6-12
MedComm (2020). 2025-4-24
本文引用的文献
Science. 2020-2-7
J Biomed Nanotechnol. 2019-12-1
Biomed Pharmacother. 2019-10-16
Diabetes Metab Syndr Obes. 2019-9-3